论文部分内容阅读
应用免疫组化ＢＡ法对４７例甲状腺癌和２６例甲状腺瘤进行了ＥＲ、ＰＲ测定。结果显示，ＥＲ、ＰＲ阳性率在腺癌分别为５７．４％、５９．６％；在腺瘤分别为６５．４％、７３．１％。腺癌与腺瘤之间以及腺癌各组织学类型之间无显著差异，但与肿瘤大小以及有无淋巴结转移有明显关系，肿瘤直径≤２ｃｍ者ＥＲ、ＰＲ阳性率明显高于直径＞２ｃｍ者；无淋巴结转移者明显高于有淋巴结转移者（Ｐ＜０．０５）。认为甲状腺癌性激素受体的检测对预测预后有一定参考意义
ER and PR were measured in 47 cases of thyroid cancer and 26 cases of thyroid tumor by immunohistochemical BA method. The results showed that the positive rates of ER and PR were 57.4% and 59.6% in adenocarcinoma and 65.4% and 73.1% in adenoma, respectively. There was no significant difference between adenocarcinoma and adenoma and histological types of adenocarcinoma, but there was a significant relationship with tumor size and lymph node metastasis. The positive rate of ER and PR in tumor diameter ≤2cm was significantly higher than that in diameter >2cm. No lymph node metastasis was significantly higher than those with lymph node metastasis (P<0.05). It is considered that the detection of sex hormone receptor in thyroid cancer has certain reference significance for predicting prognosis.